Beech: Treating pregnancy complications without affecting the fetus

For decades, drug development for pregnancy complications has been paralyzed by fear of harming the fetus — leaving physicians with few safe options to treat even life-threatening maternal conditions. Beech aims to break that impasse by developing antibody therapies engineered to avoid placental transfer, enabling treatment of complications such as preeclampsia without exposing the fetus to therapeutic risk.

Switzerland-based Beech Biotech S.A. is applying its approach first to preeclampsia, a condition involving multiple interconnected pathways causing placental dysfunction, maternal systemic inflammation and endothelial damage...